Certified for Three Years Starting from September 15
Hanmi Pharmaceutical announced on October 22 that it was selected as an "Outstanding Company for Employee Invention Compensation in 2025," a designation organized by the Intellectual Property Office under the Prime Minister's Office and the Korea Invention Promotion Association on September 15.
The Outstanding Company for Employee Invention Compensation certification system recognizes companies that succeed the rights to technologies invented by employees during their work and provide fair compensation. To obtain certification, companies must submit objective evidence such as internal regulations and compensation records. Multiple verification processes are applied to ensure fairness and transparency, and the review is conducted strictly according to legal standards.
Certified companies are granted benefits such as priority examination for patents, utility models, and designs, reductions in annual fees, and preferential points when applying for government support programs. Hanmi Pharmaceutical's certification as an Outstanding Company for Employee Invention Compensation is valid for three years from September 15.
In particular, Hanmi Pharmaceutical is further enhancing its compensation system to reflect the unique characteristics of the pharmaceutical industry. The pharmaceutical sector is based on a long development cycle that includes research, development, intellectual property management, clinical trials, and regulatory approval. This process cannot be completed by the ideas of a single individual; organic cooperation among various departments is essential. In addition, despite the low probability of success, significant capital investment, advanced research facilities, production infrastructure, and sophisticated systems must be sustained over the long term.
Choi Inyoung, Head of Hanmi Pharmaceutical’s R&D Center, stated, "Innovative new drugs are the result of not only research and development but also clinical trials, regulatory approval, marketing, production, quality, and the collective capabilities and ongoing investment of the entire company. We aim to respect these achievements and establish a balanced compensation system, and this certification as an Outstanding Company for Employee Invention Compensation is proof of that."
Through this certification, Hanmi Pharmaceutical has received recognition from government agencies for the systematic and legitimate nature of its compensation system. With this compensation system, Hanmi Pharmaceutical plans to further advance a virtuous cycle in which employees' inventive achievements are turned into assets and given business value, while also encouraging technological development within the company and strengthening its capacity for innovation.
In addition, Hanmi Pharmaceutical leads the industry among domestic pharmaceutical companies in both the number of pharmaceutical patents held and patent applications filed, thereby securing competitiveness in intellectual property rights. According to the 2024-25 ESG Report, Hanmi Pharmaceutical holds 53 drugs registered with the Ministry of Food and Drug Safety and 43 registered patents. From 2018 to 2024, the company filed a total of 250 domestic patent applications, ranking first among major domestic pharmaceutical companies. As of the end of August, Hanmi Group as a whole holds a total of 4,513 patents, including 1,614 pending applications and 2,899 registered patents.
Park Jaehyun, CEO of Hanmi Pharmaceutical, stated, "In the global pharmaceutical market, we are focusing on developing innovative therapies based on our independent research capabilities, creating differentiated value by developing technologies that surpass the limitations of existing treatments. The innovation DNA deeply rooted throughout Hanmi's organizational culture will strengthen our patent competitiveness and serve as the driving force for sustainable growth in the global market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
